The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Increased Need for Thyroxine in Women with Hypothyroidism during Estrogen Therapy
Open accessAbstract
BACKGROUND: Women with hypothyroidism that is being treated with thyroxine often need higher doses when they are pregnant. Whether this need can be attributed solely to estrogen-induced increases in serum thyroxine-binding globulin or whether other factors are involved is not known. METHODS: In 11 postmenopausal women with normal thyroid function and 25 postmenopausal women with hypothyroidism treated with thyroxine, I assessed thyroid function before they started estrogen therapy and every 6 weeks for 48 weeks thereafter. The women with hypothyroidism included 18 women receiving thyroxine-replacement therapy and 7 women receiving thyrotropin-suppressive thyroxine therapy. On each occasion, serum thyroxine, free thyroxine, thyrotropin, and thyroxine-binding globulin were measured. RESULTS: In the women with normal thyroid function, the serum free thyroxine and thyrotropin concentrations did not change, whereas at 12 weeks the mean (+/-SD) serum thyroxine concentration had increased from 8.0+/-0.9 microg per deciliter (103+/-12 nmol per liter) to 10.4+/-1.5 microg per deciliter (134+/-19 nmol per liter, P<0.001) and the serum thyroxine-binding globulin concentration had increased from 20.3+/-3.5 mg per liter to 31.3+/-3.2 mg per liter, P<0.001). The women with hypothyroidism had similar increases in serum thyroxine and thyroxine-binding globulin concentrations during estrogen therapy, but their serum free thyroxine concentration decreased from 1.7+/-0.4 ng per deciliter (22+/-5 pmol per liter) to 1.4+/-0.3 ng per deciliter (18+/-4 pmol per liter, P<0.001) and their serum thyrotropin concentration increased from 0.9+/-1.1 to 3.2+/-3.1 microU per milliliter (P<0.001). The serum thyrotropin concentrations increased to more than 7 microU per milliliter in 7 of the 18 women in the thyroxine-replacement group and to more than 1 microU per milliliter in 3 of the 7 women in the thyrotropin-suppression group. CONCLUSIONS: In women with hypothyroidism treated with thyroxine, estrogen therapy may increase the need for thyroxine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examples of drugs that increase serum TBG from insignificant to significant degrees, include estrogen (201), tamoxifen (202), raloxifene (203), clofibrate (204), opioids (205), mitotane (206), fluorouracil (207), and capecitabine (208).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [201]
In the citing paper
“With respect to the classic case of estrogen treatment in postmenopausal women, such therapy was associated with an increase in mean TSH concentration from 0.9mIU/L to approximately 3.2 mIU/L 12 weeks after initiation of estrogen therapy in a prospective nonrandomized study (201).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [201]
In the citing paper
“Conditions increasing the serum TBG concentration (eg, elevated estrogen levels) or enhancing the renal clearance of serum proteins (eg, nephrotic syndrome) can reduce the bioavailability of LT4 (34–36).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [34]
In the citing paper
“Estrogen can increase TBG and albumin concentrations and decrease FT4 levels, whereas androgen has the opposite effects (34, 91).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [34]
In the citing paper
“In postmenopausal women taking LT4, the initiation of oestrogen therapy was associated with increases in serum TBG, TT4 and TSH, and a decrease in the serum FT4 concentration [ 89 ].”
From Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults (2022) · cites this paper as [89]
Citations
Cites
Maternal and Fetal Thyroid Function
Epstein, F. H., Burrow, G. N., Fisher, D. A., & Larsen, P. R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311608 · Cited by 720
Increased need for thyroxine during pregnancy in women with primary hypothyroidism
Mandel, S. J., Larsen, P. R., Seely, E. W., & Brent, G. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230204 · Cited by 360
Levothyroxine Therapy in Patients with Thyroid Disease
Mandel, S. J., Brent, G. A., & Larsen, P. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-6-199309150-00009 · Cited by 324
Ain, K. B., MORI, Y., & Refetoff, S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-4-689 · Cited by 310
Wood, A. J. J., & Toft, A. D. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407213310307 · Cited by 168
Thyroxine Transport Proteins of Plasma. Molecular Properties and Biosynthesis
ROBBINS, J. J., Cheng, S.-Y., Gershengorn, M. C., Glinoer, D., CAHNMANN, H. J., & EDELNOCH, H. (1978) · Elsevier eBooks · doi:10.1016/b978-0-12-571134-0.50017-x · Cited by 123
THE EFFECT OF ESTROGENS UPON THE PERIPHERAL METABOLISM OF THYROXINE *†
Dowling, J. T., Freinkel, N., & Ingbar, S. H. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104127 · Cited by 83
Thyroid associated components in serum during normal pregnancy
Skjöldebrand, L., Brundin, J., Carlström, A., & Pettersson, T. (1982) · European Journal of Endocrinology · doi:10.1530/acta.0.1000504 · Cited by 74
Arafah, B. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00002 · Cited by 71
Williams Textbook of endocrinology
Wilson, J. D., & Williams, R. H. (1998) · Cited by 56
Research works printed but not linked: 1
- Robbins J, 1978, Recent Prog Horm Res, 34, 477
Cited by
Sorted by citations
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Examples of drugs that increase serum TBG from insignificant to significant degrees, include estrogen (201), tamoxifen (202), raloxifene (203), clofibrate (204), opioids (205), mitotane (206), fluorouracil (207), and capecitabine (208).”
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Alexander, E. K., Marqusee, E., Lawrence, J., Jarolim, P., Fischer, G. A., & Larsen, P. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040079 · Cited by 633
Roberts, C. G., & Ladenson, P. W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15696-1 · Cited by 567
Metadata
- Authors
- Arafah, B. M.
- Affiliations
- University Hospitals of Cleveland (US)
- Corresponding author
- Arafah, Baha M.
- ORCID
- Arafah, Baha M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-06-07
- Volume
- 344
- Issue
- 23
- Pages
- 1743-1749
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2314885285
- Cited by
- 267
- References
- 13
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 6 · 2023: 12 · 2022: 9 · 2021: 22 · 2020: 5 · 2019: 13 · 2018: 9 · 2017: 4 · 2016: 5 · 2015: 13 · 2014: 12 · 2013: 10 · 2012: 10
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- hypothyroidism, estrogen therapy, thyroxine-binding globulin, free thyroxine, thyroid-stimulating hormone, postmenopausal women, thyroxine replacement, thyroid function monitoring, hormone replacement therapy, thyroid autoimmunity, thyroid cancer risk
- MeSH terms
- Adult, Estrogens, Conjugated (USP), Female, Humans, Hypothyroidism, Medroxyprogesterone, Middle Aged, Reference Values, Thyroid Function Tests, Thyroid Gland, Thyroid Neoplasms, Thyrotropin, Thyroxine, Thyroxine-Binding Proteins, Postmenopause, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
